



MINISTÈRE
DE L'ENSEIGNEMENT
SUPÉRIEUR
ET DE LA RECHERCHE

*Liberté
Égalité
Fraternité*



12.04.2024 09:00 • 17:00

— En ligne

Journée d'information

Mission Cancer: session webinaire 12 AVR 2024, 14:30 – 15:30

Horizon Europe en bref

9^e PCRI: 2021-2027

« Le programme de financement de la R&I le plus ambitieux jamais entrepris »

- Budget : 95,5 Md€
- Continuité avec Horizon 2020 : « **une évolution, pas une révolution** »
- Politique de Science ouverte
- Une plus grande ouverture sur l'international

- **NOUVEAUTÉS**
 - Conseil Européen de l'Innovation
 - **Missions**
 - Partenariats



La santé dans Horizon Europe

13,6 Md€

Pilier 1
Science d'excellence

Conseil européen de la recherche

Actions Marie Skłodowska-Curie

Infrastructures de recherche

53,5 Md €

Pilier 2
Problématiques mondiales et compétitivité industrielle et européenne

Santé

8,24Md€

Culture, créativité et société inclusive

Sécurité civile pour la société

Numérique, industrie et espace

Climat, énergie et mobilité

Alimentation, bioéconomie, ressources naturelles, agriculture et environnement

Centre commun de recherche

25 Md €

Pilier 3
Europe plus innovante

Conseil européen de l'innovation

Écosystèmes européens d'innovation

Institut européen d'innovation et de technologie

Élargir la participation et renforcer l'espace européen de la recherche

3,4 Md €

Élargir la participation et développer l'excellence

Réformer et consolider le système européen de R&I

Le Cluster Santé

6 domaines d'intervention



Planification stratégique

- 2021-2024
- 2025-2027



Priorités politiques de l'UE (Transition verte et numérique)
Orientations Stratégiques pour la R&I
"Expected impacts" – Destinations (Santé)



**Programme de travail
Santé**

Partenariats en santé


Mission Cancer

La Mission Cancer dans Horizon Europe




Five main **operational goals** = Five missions

- Combination of **research** projects, **policy** measures or even legislative initiatives to achieve a common goal that could not be achieved through individual actions.
- **Transversality** (between disciplines / different sectors)
- **Co-design** (with citizens, local stakeholders..)



La Mission Cancer dans Horizon Europe

2018



DG RTD
09/2020



DG Santé
02/2021



DG RTD
09/2021




“ Missions’ goal is to involve citizens and stakeholders more closely in setting research priorities, but not only, which will lead to equal access for everyone in Europe to the best of European innovation & research resources, and global know-how”

Cancer Mission Actions

- ✓ Innovation
- ✓ Risk taking
- ✓ Citizen Engagement
- ✓ Commitment at National level
- ✓ Commitment of all
- ✓ Equitable Access

Objectif : « D'ici 2030, plus de 3 millions de vies sauvées, vivre mieux et plus longtemps »



La mission cible **l'ensemble du continuum du contrôle du cancer**, de la prévention des facteurs de risques, l'amélioration des diagnostics et des traitements des patients, au soutien des survivants dans leur qualité de vie

→ **Programme de travail dédié**




EUROPEAN UNION

Cancer Mission - WP2021-2022-2023

EU MISSIONS
CANCER 

Overall approach

- Apply mission-guiding principles
- Develop mission projects clusters
- Synergies with Europe's Beating Cancer Plan
- Total budget 2021-2023: € 365 M*



- Develop new methods and technologies for screening and early detection
HORIZON-MISS-2021-CANCER-02-01
- Improving and upscaling primary prevention of cancer through implementation research
HORIZON-MISS-2022-CANCER-01-01
- Enhance cancer prevention through behaviour change
HORIZON-MISS-2023-CANCER-01-02

- Pragmatic clinical trials to optimise treatment for cancer patients
HORIZON-MISS-2022-CANCER-01-03
- Strengthen research capacities of comprehensive cancer infrastructures
HORIZON-MISS-2022-CANCER-01-02
- Pragmatic clinical trials minimally invasive diagnostics
HORIZON-MISS-2023-CANCER-01-03

- Develop and validate a set of quality of life measures for cancer patients and survivors
HORIZON-MISS-2021-CANCER-02-02
- Towards the creation of a European Cancer Patient Digital Centre
HORIZON-MISS-2022-CANCER-01-04:
- Improve quality of life for survivors of childhood cancer (Best practices and tools)
HORIZON-MISS-2023-CANCER-01-04:

- Preparing UNCAN.eu, a European initiative to understand cancer
HORIZON-MISS-2021-UNCAN-01-01
- Better understand healthy versus cancer cells at individual and population level
HORIZON-MISS-2021-CANCER-02-03
- Better understand tumour-host interactions in cancer patients
HORIZON-MISS-2023-CANCER-01-01

Creation of national cancer mission hubs to support the implementation of the Mission on Cancer - HORIZON-MISS-2022-CANCER-01-05

Les objectifs pour 2024

Draft WP 2023-2025

Obj. Understanding: implementation of a broad portfolio of **cancer use cases**, preparing the operationalisation of the **UNCAN.eu research data platform**.

Obj. Prevention: support the development of tests for **early detection of heritable cancers**.

Obj. Diagnosis and treatment: action to facilitate coordination among charities and other relevant stakeholders for the establishment and implementation of a **funding programme for pragmatic clinical trials**.

Obj. Quality of life: enhance the **quality of life for survivors of adolescent and young adult (AYA) cancer** by improving the understanding and management of late effects of treatments. In addition, under the same objective, the development of a **pilot information portal for cancer patients, survivors and caregivers**, which will form the basis of the future European Cancer Patients Digital Centre.

>>> + **Dialogue:** to foster the **dialogue at national level between relevant actors and stakeholders**, for example to further support the establishment and implementation of both the **UNCAN.eu and ECPDC** digital platforms.

6 thématiques ; 119 M€ - Deadline 18 SEP 2024

**Draft WP 2023-2025
Publications 17 avril 2024**

Table 1/2	HORIZON-MISS-2024-CANCER-01-01: Use cases for the UNCAN.eu research data platform	HORIZON-MISS-2024-CANCER-01-02: Support dialogue towards the development of national cancer data nodes	HORIZON-MISS-2024-CANCER-01-03: Accessible and affordable tests to advance early detection of heritable cancers in European regions
Expected EU contribution per project	30,00 M€	3,00 M€	10,00 à 12,00 M€
Total Indicative budget for the topic	30,00 M€	3,00 M€	35,00 M€
Type of Action	RIA	CSA	IA
Expected outcome	- operationalise the UNCAN.eu research data platform through a series of use-cases. ⇔ develop tools supporting researchers to access, manage and analyse cancer digital data...	- Data resource to improve our understanding of cancer, advance prevention and early detection strategies, facilitate the delivery of personalised care, and better address the quality of life of cancer patients and survivors ⇔ Cancer data nodes	- Decisive action on early detection using easy-to-use, specific and sensitive, affordable and accessible genetic multi-omics or other biomarker-based tests to diagnosing and treating cancer with an underlying heritable genetic risk at an earlier, potentially curable stage, and with fewer side-effects

Draft WP 2023-2025

Table 2/2	HORIZON-MISS-2024-CANCER-01-04: Support a pragmatic clinical trial programme by cancer charities	HORIZON-MISS-2024-CANCER-01-05: Improving the understanding and management of late-effects in adolescents and young adults (AYA) with cancer	HORIZON-MISS-2024-CANCER-01-06: An information portal for the European Cancer Patient Digital Centre
Expected EU contribution per project	3,00 M€	4,00 à 6,00 M€	12,00 M€
Total Indicative budget for the topic	3,00 M€	36,00 M€	12,00 M€
Type of Action	CSA	RIA	IA
Expected outcome	<p>- Pragmatic clinical trials focus on choosing between care options. Pragmatic trials evaluate effectiveness, the effect of treatment in routine (real-world) clinical practice.</p> <p>⇔ examples: treatment versus active surveillance in patient management,</p> <p>⇔ a combination of treatment interventions,</p> <p>⇔ determination of optimal dose and dose schedules,</p> <p>⇔ comparative effectiveness of different treatment interventions.</p>	<p>- Increased awareness and understanding in AYA cancer survivors</p> <p>-Ensure accessibility and re-usability of data</p> <p>- Identification of effective interventions and best practices to support AYA patients and survivors in preventing, reducing, managing late-effects, promoting optimal health outcomes and overcoming disparities between regions;</p> <p>- Improved quality of life and long-term outcomes for AYA cancer survivors, including improved physical, emotional, and social well-being.</p>	<p>- Improving the quality of life of cancer patients, survivors and their families through the future European Cancer Patient Digital Centre (ECPDC) to facilitate their access to quality information and data sharing.</p> <p>=> to design, develop, deploy and operate a pilot information portal of the ECPDC covering all the spectrum of the cancer patient journey.</p> <p>=> Specific AI tools to timely update the information provided and facilitate the user experience.</p>

Actions complémentaires non soumises à appels à projets

Synergies with other missions, exemples:

- healthier living environment and more active lifestyles;
- pollution in the ocean and waters;
- better water and air quality, reduce food contamination ...
 - 0,5 M€ onto 2024 clusters budget
 - Indicative timetable: 3rd Quarter 2024 - 1st Quarter 2025 ; request during the GA preparation

Policy dialogues on international collaborations:


- Enhance cooperation with 3rd countries including research, policy makers and stakeholders;
- ⇔ 0,5 M€ onto 2024 clusters budget
- Indicative timetable: 3rd Quarter 2024 - 1st Quarter 2025

Communication, citizen engagement and stakeholder consultation:

- dissemination to inform citizen ans stakeholders on Mission activities;
- events to engage citizen, patients and caregivers;
- experts group meetings...
 - 3,47 M€ onto 2024 clusters budget
 - Indicative timetable: 1st Quarter 2024 - 4th Quarter 2025

Monitoring


- A study to further develop a framework for the monitoring of the implementation of the Mission on Cancer, in synergy with the monitoring framework of the Europe's Beating Cancer Plan.
 - 0,5 M€ onto 2024 clusters budget
 - Indicative timetable: Q1 2024

 **EUROPEAN UNION**
Missions working together

Important **synergies** link the objectives of the EU Mission on Cancer to the other EU Missions. They enable the different Missions to mutually reinforce one another and improve outcomes. This is especially true when it comes to **prevention and improving quality of life**:


- 1 Limiting the use of cars in urban areas, digitalizing transport operations or developing public transport, and developing better walking and cycling connections will produce a healthier living environment and more active lifestyles through the **Climate Neutral and Smart Cities Mission**.
- 2 By preventing, minimising, remedating and monitoring pollution in the ocean and waters, the **Oceans Mission** will support the prevention of cancer.
- 3 By promoting a pollution-free environment, organic farming, safe non-polluted food and healthier diets, the **Soil Health and Food Mission** will ensure better water and air quality, and reduce food contamination with chemicals, which is key to reducing cancer.
- 4 Increasing air quality, combating air pollution, improving the quality of life and protecting vulnerable people, including those at higher risk of cancer, are key objectives of the **Adaptation to Climate Change Mission**.

In turn, the Mission on Cancer, through actions on sustainable procurement (e.g. to increase energy efficiency of healthcare services and buildings) and prevention of contamination of food and water with pharmaceuticals/chemicals, will contribute to the other Missions achieving their goals.

 **EUROPEAN UNION**
Engaging citizens

To take account of citizens' views and needs, the Mission involves them in the design, implementation and review of mission actions to ensure they are listened to, represented and engaged with throughout.

Different activities such as workshops, focus groups and surveys will target citizens of different walks of life, including young people, patients and their families and caregivers, and the elderly. To foster participation, each activity will be adapted to its specific audience and national language.



Types d'action

✓ RIA - Research and Innovation Actions

→ recherche fondamentale et appliquée, développement et l'intégration de technologie, essais et validation d'un prototype à petite échelle dans un laboratoire ou un environnement simulé

Taux de financement européen 100%

✓ IA - Innovation Actions

→ prototypage, essais, démonstration ou pilotes, validation du produit à grande échelle, première commercialisation. Les projets peuvent inclure des activités limitées de recherche et de développement

**Taux de financement européen
100% pour les entités publiques - 70% pour les entités privées**

✓ CSA - Coordination and Support Actions

→ études de design pour de nouvelles infrastructures, activités complémentaires de planning stratégique, mise en réseau et la coordination entre programmes dans différents pays

Taux de financement européen 100%

Règles de participation

Idem Horizon Europe

✓ Conditions d'éligibilité d'un consortium

Minimum 3 entités légales indépendantes et établies dans un Etat Membre ou Etat Associé différent, dont au moins une établie dans un Etat Membre

✓ Condition de participation

Toute entité légale de tout pays peut participer (organisme de recherche, université, PME, associations, villes....)

✓ Pays éligibles au financement

- Etats-Membres
- Etats-Associés :

- Albanie, Arménie, Bosnie-Herzégovine, Îles Féroé, Géorgie, Islande, Israël, Kosovo, Moldavie, Monténégro, Macédoine du Nord, Norvège, Nouvelle Zélande, Serbie, Tunisie, Turquie, Ukraine, **UK depuis 1^{er} janvier 2024**

Pays-Tiers : certains pays à faibles et moyens revenus sont automatiquement éligibles au financement (Programme Guide Horizon Europe)

✓ CAS PARTICULIER

Association proche: **Corée du Sud validée**, Canada et Maroc en cours de négociation

USA n'est pas éligible au financement dans la mission Cancer

Suisse: pas d'accord d'association encore. Les institutions Suisses sont financées directement par leur agence nationale.

Les projets financés en 2021-2023



Votre idée est-elle déjà dans l'un de ces projets ?
Sourcer des partenaires
Des possibilités de synergies avec ces projets ...



Acronym		Title	Coordinator Country	website
Call: HORIZON-MISS-2021-UNCAN 01-01 – Preparing UNCAN.eu, a European initiative to understand cancer				
UNCAN	CSA	A Coordination and Support Action to prepare UNCAN.eu platform	France	Home - Uncan.eu
Call: HORIZON-MISS-2021-CANCER-02-01— Develop new methods and technologies for cancer screening and early detection				
MAMMOSCREEN	RIA	Innovative and safe microwave-based imaging technology to make breast cancer screening more accurate, inclusive and female-friendly	Italy	The MammoScreen Project
ONCOSCREEN	RIA	A European “shield” against colorectal cancer based on novel, more precise and affordable risk-based screening methods and viable policy pathways	Greece	oncoscreen.health
SANGUINE	RIA	Early detection and screening of hematological malignancies	Israel	SANGUINE - Early Diagnostics of Hematological Malignancies (Blood Cancer) Cancer care (sanguine-project.eu)
PANCAID	RIA	PANcreatic CAncer Initial Detection via liquid biopsy	Greece	Home - PANCAID (pancaid-project.eu)
THERMOBREAST	RIA	An innovative non-contact and harmless screening modality set to change the course of breast cancer detection and patient monitoring	Israel	ThermoBreast – An innovative non-contact and harmless screening modality set to change the course of breast cancer detection and patient monitoring
DIOPTRA	RIA	Early dynamic screening for colorectal cancer via novel protein biomarkers reflecting biological initiation mechanisms	Greece	Home DIOPTRA - DIOPTRA project (diontra-project.eu)
Call: HORIZON-MISS-2021-CANCER-02-02— Develop and validate a set of quality of life and patient preference measures for cancer patients and survivors				
EuonQol	RIA	Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe	Italy	EUonQol

Call: HORIZON-MISS-2021-CANCER 02-03 - Better understanding of the impact of risk factors and health determinants on the development and progression of cancer

GENIAL	RIA	Understanding Gene ENvironment Interaction in ALcohol-related hepatocellular carcinoma	Belgium	Home (genial-project.com)
MELCAYA	RIA	Novel health care strategies for melanoma in children, adolescents and young adults	Spain	Home - MELCAYA
DISCERN	RIA	Discovering the causes of three poorly understood cancers in Europe	France	DISCERN: The Project (who.int)
ELMUMY	RIA	Elucidation of risk factors and health determinants associated with PROGRESSION of Monoclonal Gammopathies to Multiple Myeloma	Greece	Home Elmumy
LUCIA	RIA	Understanding Lung Cancer Related Risk Factor and their Impact	Israel	Home LUCIA (technion.ac.il)

Call: HORIZON-MISS-2022-CANCER-01-01—Improving and upscaling primary prevention of cancer through implementation research

PIECES	RIA	Towards large-scale adaption and tailored implementation of evidence based primary cancer prevention programmes in Europe and beyond	SPAIN	-
4P-CAN	RIA	Personalised cancer primary prevention research through citizen participation and digitally enabled social innovation	ROMANIA	Home - 4P-CAN
PREVENT	RIA	Improving and upscaling primary prevention of cancer by addressing childhood obesity through implementation research - the PREVENT approach	Greece	Home - PREVENT (preventproject.eu)
CPW	RIA	Cancer Prevention at Work (CPW): Occupational health surveillance in the implementation of prevention of infection-related cancer	Italy	www.cancerpreventionatwork.eu
ONCODIR	RIA	Evidence-based participatory decision making for cancer prevention through implementation research	Greece	Home - ONCODIR
CO-CAPTAIN	RIA	Cancer prevention among individuals with mental ill-health: co- adapting and implementing patient navigation for primary cancer prevention	Austria	Home - CO-CAPTAIN (cocaptain.eu)

Call: HORIZON-MISS-2022-CANCER-01-02 – Strengthening research capacities of Comprehensive Cancer Infrastructures

CCI4EU	CSA	Comprehensive Cancer Infrastructure in Europe (CCI4EU)	Italy	CCI4EU
--------	-----	--	-------	------------------------

Call: HORIZON-MISS-2022-CANCER-01-03 – Pragmatic Clinical trials to optimize treatments for patients with refractory cancers

LEGATO	RIA	Lomustine with or without re-irradiation for first progression of glioblastoma: a pragmatic randomised phase III study	Belgium	LEGATO (legato-horizon.eu)
STREXIT2	RIA	A pragmatic clinical study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with high-risk retroperitoneal sarcoma	Belgium	STREXIT2 (strexit-horizon.eu)
PRIME-ROSE	RIA	Precision cancer medicine repurposing system using pragmatic clinical trials	Norway	PRIME-ROSE: Advancing Precision Cancer Medicine in Europe (matrix-fkb.no)

SALVOVAR	RIA	A European multidisciplinary clinical project meant to improve the management of patients with poor prognostic ovarian cancer after neoadjuvant chemotherapy: restoring hope, salvaging lives	France	SalvOvar - Restoring hope, Salvaging lives
DE-ESCALATE	RIA	Intermittent androgen deprivation therapy in the era of androgen receptor pathway inhibitors; a phase 3 pragmatic randomised trial	Belgium	DE-ESCALATE (deescalate-horizon.eu)
IntReALL 2020	RIA	International Study for Treatment of Childhood Relapsed ALL 2020	Germany	Home - IntReALL (intreall2020.eu)
IMPORTANT	RIA	Pragmatic clinical trials to optimise treatments for patients with refractory cancers	Sweden	https://www.oru.se/english/research/research-projects/rp/?rdb=p2568
SAGITTARIUS	RIA	The Sagittarius trial: a precision medicine pragmatic trial leveraging blood-based tumour genomics to optimise treatment in operable stage III and high-risk stage II colon cancer patients	Italy	Homepage - English - Sagittarius Horizon (sagittarius-horizon.eu)
PragmaTIL	RIA	Pragmatic approach to Adoptive Cell Therapy (ACT) using Tumour Infiltrating Lymphocytes (TIL) in selected solid tumours	Spain	PragmaTIL
CARE1	RIA	First line randomised study platform to optimise treatment in patients with metastatic renal cell carcinoma	France	CARE1: A European Study on First-Line Treatment of Metastatic Kidney Cancer Gustave Roussy

Call: HORIZON-MISS-2022-CANCER-01-04 – Towards the creation of a European Cancer Patient Digital Centre

European Patient Digital Centre	Procurement	Study providing an operational concept for a European cancer patient digital centre	Germany	Projects ECPDC (hidih.org)
---------------------------------	-------------	---	---------	--

Call: HORIZON-MISS-2022-CANCER-01-05 – Establishing of national cancer mission hubs and creation of network to support the Mission on Cancer

ECHoS	CSA	ECHOS – Establishing of cancer mission hubs: networks and synergies	Portugal	https://cancermissionhubs.eu
Gliomatch	RIA	The malignant Glioma immuno-oncology matchmaker: towards data-driven precision medicine using spatially resolved radio-multiplexomics	Belgium	Project – GLIOMATCH
Hit-Glio	RIA	Targeting tumour-host interactions in paediatric malignant gliomas to reinvigorate immunity and improve radio- and immunotherapy efficacy	Poland	HIT-GLIO - geneXplain
Multir	RIA	Multi-tumour based prediction and manipulation of immune response	France	-
Thrive	RIA	Tumour-host interactions in liver cancer of childhood and adults	Spain	https://thrive-liver-cancer.eu
Arturo	RIA	Assessing the role of intratumoral microbiota in therapy responses using patient derived tumor-on-chip	France	-
Spacetime	RIA	SPAtial Analysis of Cancer Evolution in the Tumour Immune MicroEnvironment	Netherlands	-

Call: Horizon-MISS-2023-CANCER-01-02 – Enhancing primary care prevention through sustainable behavioural change

MELIORA	RIA	Multimodal engagement and sustainable lifestyle interventions optimising breast cancer risk reduction supported by artificial intelligence	Greece	-
SUNRISE	RIA	SUstaiNable inteRventions and healthy behaviours for adoleScent primary prEvention of cancer with digital tools	Greece	-
iBeCHANGE	RIA	Addressing psychosocial and lifestyle risk factors to promote primary care prevention: an integrated platform to promote behavioural change	Italy	-

Call: Horizon-MISS-2023-CANCER-01-03 – Pragmatic clinical trials on minimally invasive diagnostics

RESOLVE	RIA	Residual disease assessment in hematologic malignancies to improve patient-relevant outcomes across Europe	Germany	-
PREMO COLLAB	RIA	Personalised response monitoring in oncology: co-creating clinical trials in advanced breast cancer	Denmark	https://www.premiocollob.eu
ENDEAVOR	RIA	Endoscopic brush cytology and single cell clonal dynamics of early esophageal adenocarcinoma for defining cost effective surveillance strategies and prediction of cancer recurrence	Belgium	-
DEFINITIVE	RIA	Diagnostic HER2DX-guided treatment For patients with early-stage HER2-positive breast cancer	Spain	-
MONALISA	RIA	A SIOPEN pragmatic clinical trial to Monitor Neuroblastoma relapse with Liquid biopsy Sensitive Analysis	Belgium	https://smit.vub.ac.be/project/monalisa

Call: Horizon-MISS-2023-CANCER-01-04 – Establish best practices and tools to improve the quality of life for childhood cancer patients, survivors and their families in European regions

eQuoL	IA	e-Health tools to promote Equity in Quality of Life for childhood to young adulthood cancer patients after treatment/survivors and their families - a PanEuropean project supported by PanCare and Harmonic consortia	France	https://cordis.europa.eu/project/id/101136549
-------	----	---	--------	---

Europe's Beating Cancer Plan projects

[Europe's Beating Cancer Plan, with projects covering prevention, early detection, diagnosis and treatment, and improved quality of life for cancer patients and survivors. \(europa.eu\)](http://europa.eu)

EIC Accelerator Call - Novel biomarker-based assays to guide personalised cancer treatment

Histotype Px	EIC accelerator	Precision biomarker based on digital pathology and artificial intelligence to guide fast and cost-effective personalized treatment decision support for colorectal cancer patients	DoMore Diagnostics, Norway	DoMore Diagnostics
IOO - Improving IO	EIC accelerator	IOO: a novel assay to predict patient response to immune checkpointinhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology	Fastbase Solutions, Spain	WWW.FASTBASESOLUTIONS.COM
NTX1088	EIC accelerator	First-in-class anti-PVR mAb NTX1088 - a novel oncology drug thatunlocks the power of human immune system and revolutionizes cancer care	Nectin Therapeutics, Israel	http://www.nectintx.com/
QlandQD	EIC accelerator	The first IVDR-approved commercial software solutions for AI- powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancer	Qlucore,Sweden	www.qlucore.com

Digital Europe Programme

EUCAIM		European Federation for Cancer Images	Austria	Home - Cancer Image Europe
--------	--	---------------------------------------	---------	---

Aide au montage (1)

Montage de Réseaux Scientifiques Européens ou Internationaux (MRSEI)

Soutient l'**aide au montage et à l'animation** d'un réseau scientifique européen ou international **coordonné par** impliquant les membres du réseau qui sera déposé à un appel européen ou international.

Subvention: 35 k€ pour une durée maximale de 24 mois

Coût éligibles:

- ✓ communication, organisation et animation de rencontres, ateliers, symposium, etc...
- ✓ prestation de service à hauteur maximale de 10 000€ pour appuyer le coordinateur dans le montage du futur projet.

Prochaines dates de soumission :

- ✓ 12 septembre 2024



Toutes les infos

<https://anr.fr/fr/detail/call/montage-de-reseaux-scientifiques-europeens-ou-internationaux-mrsei-2024/>

Trop tard pour les appels Mission Cancer 2024
Mais y penser pour les appels ultérieurs

Aide au montage (2)

Le diagnostic Partenariat pour les projets collaboratifs des entreprises

Le Diagnostic Partenariat Technologique International (Diag PTI) de Bpifrance vise à faciliter l'accès des entreprises françaises aux appels à projets collaboratifs de recherche, développement et innovation, au premier rang desquels Horizon Europe.

En pratique, le Diag PTI comprend



- une multitude de possibilités d'accompagnement sur toute la partie de montage du projet collaboratif : *recherche de partenaires, négociation de l'accord de consortium, écriture de dossier, ...* etc.
- une subvention qui couvre 50 % du montant TTC de la prestation d'un Expert Conseil
- une prestation adaptée aux besoins de l'entreprise : *jusqu'à 25k€ HT si l'entreprise est cheffe de file, jusqu'à 5k€ HT si l'entreprise fait partie d'un consortium sans en être à la tête*
- un dépôt *au fil de l'eau*, qui s'adapte à la timeline de l'entreprise
- une demande facilitée en ligne, sur le site de Bpifrance
- une *réponse rapide* sous 2 semaines

Quelques sources d'information sur la Mission Cancer

Publication des appels prévue le 17 avril 2024 !

- Pour en savoir plus sur la Mission Cancer

https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe/eu-missions-horizon-europe/eu-mission-cancer_en

- Un diaporama sur la Mission Cancer dans son ensemble

https://research-and-innovation.ec.europa.eu/document/download/23b773b4-ea6d-4e38-8288-334fb6c4279c_en?filename=ec_rtd_eu-missions-cancer-leaflet-en.pdf

- Evènement EU Missions and cross-cutting activities info days, 25-26 avril 2024, 9h30 (GMT+2h)

<https://research-innovation-community.ec.europa.eu/events/3WjiVunxm0t5j4zQlVax3Q/overview>

- [Wébinar DG Santé 5 juin 2024, use case >>>](#)

https://health.ec.europa.eu/document/download/3fb38e79-c456-440c-9b21-5f4a314ee038_en?filename=policy_20240605_ag_en.pdf

- **Et bien sur votre PCN Santé** [>>>](https://www.horizon-europe.gouv.fr/cluster-1-sante)

PCN Santé – Qui sommes-nous ?



Virginie Sivan, MESRI

Coordination PCN et représentation au comité de programme Santé



Vania Rosas-Magallanes



Catherine Tostain-Desmares



Roxane Brachet



[Nous contacter : pcn-sante@recherche.gouv.fr](mailto:pcn-sante@recherche.gouv.fr)

[Nous suivre : LinkedIn](#) 

[Liste de diffusion](#)

[Web: https://www.horizon-europe.gouv.fr/cluster-1-sante](https://www.horizon-europe.gouv.fr/cluster-1-sante)